Triacef injection

Dexa Medica

Ingredients in every vial

Ceftriaxone 1 g

Each package contains

1 vial of 1 g

Other details

Dosage form:Injection
Flavour: None

W.H.O. classification

ATC Level 1: J - Antiinfectives for systemic use
ATC Level 2: J01 - Antibacterials for Systemic Use
ATC Level 3: J01D - Other Beta-Lactam Antibacterials in ATC



CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.


CAUTIONThis item may not be safe for use during lactation. Use with caution.


CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.


CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution.

Available in


Dosage information

Usual dose: 1-2 g once daily (every 24 hours).
In severe infections and in cases in which the pathogens are only moderately sensitive, the daily dosage may be increased to 4g once daily.

Usual dose: 1-2 g once daily (every 24 hours).
In severe infections and in cases in which the pathogens are only moderately sensitive, the daily dosage may be increased to 4g once daily.

Neonatus, infants and children under 12 years:
Neonatus (2 weeks)
20 – 50 mg/kg body weight once daily, not exceed 50 mg/kg body weight. The daily dosage should not exceed 50 mg/kg body weight on account of the immaturity of the infant's enzyme systems.

Infants and children (3 weeks – 12 years):
The daily dose is 20 – 80 mg/kg of body weight. For children with body weight ≥ 50 kg usual dosage is the same as adult dosage. Intravenous doses of 50 mg/kg body weight or more should be given by infusion for at least 30 minutes.

Geriatric patients:
The recommended dosages as the dosage for adults. No adjustment dosage is required in geriatric patients.

Duration of therapy:
The duration of therapy varies according to the course of the disease.
As with antibiotic therapy in general, administration of ceftriaxone should be continued for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of bacterial eradication has been obtained.

Combination therapy:
Synergy between ceftriaxone and aminoglycosides has been demonstrated with many Gram-negative bacteria. Although enhanced activity of such combinations is not always predictable, it should be considered in severe, life-threatening infections due to microorganisms such as Pseudomonas aeruginosa. As the two antibiotic agents are incompatible, they must be administered separately at the recommended dosages.

Special dosage instructions:
The treatment of meningitis in infants and children, treatment begins with doses of 100 mg/kg (up to a maximum of 4 g) once daily. As soon as the causative organism has been identified and its sensitivity determined, the dosage can be reduced accordingly.
Treatment courses that have been found effective include:

- Neisseria meningitidis 4 days
- Haemophylus influenzae 6 days
- Streptococcus pneumoniae 7 days

For the treatment of gonorrhea by penicillinase-producing and non-penicillinase-producing strains), a single intramuscular dose of 250 mg ceftriaxone is recommended.

Perioperative prophylaxis:
To prevent postoperative infections in contaminated or potentially contaminated surgery, the recommended approach - depending on the risk of infection - is a single dose of 1 to 2 g ceftriaxone administered 30 to 90 minutes prior to surgery.
In colorectal surgery, concurrent treatment of ceftriaxone with or without a 5-nitroimidazole, e.g., ornidazole (administered separately) has proven effective.

In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is intact. Only in cases of pre-terminal renal failure (creatinine clearance <10 ml/minute) the ceftriaxone dosage should not exceed 2 g daily. In patients with liver damage, there is no need for the dosage to be reduced provided renal function is intact. In cases of concomitant severe renal and hepatic dysfunction, determine the plasma concentrations of ceftriaxone at regular intervals. Patients undergoing dialysis require no additional supplementary dosing following the dialysis. Plasma concentrations should, however, be monitored, to determine if dosage adjustments are necessary, since in these patients, the elimination rate may be altered


Infections caused by bacteria which are sensitive to ceftriaxone e.g.,:
– Lower respiratory tract infections.
– Skin and skin structure infections.
– Bone and joint infections.
– Intra-abdominal infections.
– Urinary tract infections; meningitis; septicemia;
– Perioperative surgical prophylaxis infection.
– Infections in patients with impaired defense mechanisms.


The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.